Besides, we found that the therapeutic efficacy of ETRQβ-002 in experimental PAH might be associated with the time of administration, because data showed that protective effects of the vaccine in the SuHx + ETRQβ-002(s) group were better than that in the SuHx + ETRQβ-002(e) group in some aspects, including the proliferation of PA (Ki67), fibrosis of PA, and CSA of RV. This evidence concerns the gene MKI67 and pulmonary arterial hypertension.